IELSG37

IELSG37A randomized, open-label, multicentre, two-arm phase III comparative study assessing the role of mediastinal radiotherapy after Rituximab containing chemotherapy regimens to patients with newly diagnosed Primary Mediastinal Large B-Cell Lymphoma (PMLBCL)
Participants required:540 (enrolment completed)
Investigator responsible(s):M. Martelli, A.J. Davies, M. Gospodarowicz, E. Zucca
Objective(s):To evaluate the possibility to spare the radiotherapy in PMBCL patients, who have become “PET-negative” after a combined R-chemotherapy.
Publication(s):Ceriani L. et al. Training improves the interobserver agreement of the expert positron emission tomography review panel in primary mediastinal B-cell lymphoma: interim analysis in the ongoing International Extranodal Lymphoma Study Group-37 study. Hematological Oncology 2017. Link

Home | Go to Studies

Top